Algert Global LLC Has $7.20 Million Stake in BioCryst Pharmaceuticals, Inc. $BCRX

Key Points

• Algert Global LLC increased its stake in BioCryst Pharmaceuticals by 32.4% during the first quarter, acquiring an additional 234,752 shares, bringing its total ownership to 960,057 shares worth approximately $7.2 million.
• BioCryst Pharmaceuticals reported strong financial results for the last quarter, with $163.35 million in revenue, up 49.5% year-over-year, and an EPS of $0.15, exceeding analyst expectations.
• Institutional investors currently own 85.88% of BioCryst's stock, highlighting significant interest from major financial firms as several hedge funds recently increased their holdings.

Algert Global LLC lifted its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 32.4% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 960,057 shares of the biotechnology company's stock after buying an additional 234,752 shares during the quarter. Algert Global LLC owned about 0.46% of BioCryst Pharmaceuticals worth $7,200,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. E Fund Management Co. Ltd. grew its stake in BioCryst Pharmaceuticals by 42.5% during the first quarter. E Fund Management Co. Ltd. now owns 23,674 shares of the biotechnology company's stock worth $178,000 after buying an additional 7,062 shares in the last quarter. Russell Investments Group Ltd. raised its stake in BioCryst Pharmaceuticals by 269.5% during the first quarter. Russell Investments Group Ltd. now owns 103,329 shares of the biotechnology company's stock worth $775,000 after acquiring an additional 75,363 shares in the last quarter. Knott David M Jr grew its holdings in shares of BioCryst Pharmaceuticals by 4.5% during the first quarter. Knott David M Jr now owns 460,000 shares of the biotechnology company's stock worth $3,450,000 after purchasing an additional 20,000 shares during the last quarter. Nuveen LLC bought a new stake in shares of BioCryst Pharmaceuticals during the first quarter worth about $10,677,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of BioCryst Pharmaceuticals by 64.5% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,042,424 shares of the biotechnology company's stock worth $7,818,000 after purchasing an additional 408,560 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Stock Up 2.1%

BCRX traded up $0.18 during trading on Friday, hitting $8.56. The company's stock had a trading volume of 2,200,430 shares, compared to its average volume of 3,356,199. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.01 and a twelve month high of $11.31. The stock's fifty day moving average price is $8.83 and its 200-day moving average price is $8.79. The firm has a market capitalization of $1.80 billion, a P/E ratio of -47.55, a PEG ratio of 1.90 and a beta of 1.10.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.12. The business had revenue of $163.35 million during the quarter, compared to analyst estimates of $149.59 million. During the same period last year, the firm posted ($0.06) earnings per share. BioCryst Pharmaceuticals's quarterly revenue was up 49.5% compared to the same quarter last year. Equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Insider Transactions at BioCryst Pharmaceuticals

In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of the business's stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total value of $595,700.00. Following the transaction, the director directly owned 65,352 shares of the company's stock, valued at approximately $556,145.52. The trade was a 51.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 5.10% of the company's stock.

Analyst Ratings Changes

BCRX has been the topic of several research reports. Wall Street Zen upgraded BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, July 26th. Barclays boosted their price target on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a report on Wednesday, May 7th. Wedbush boosted their price target on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an "outperform" rating in a report on Monday, June 30th. HC Wainwright restated a "buy" rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. Finally, Needham & Company LLC restated a "buy" rating and set a $17.00 price target on shares of BioCryst Pharmaceuticals in a report on Monday, August 4th. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.70.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.